Arrowhead Pharmaceuticals, Inc. (ARWR) - Stock Analysis
Last updated: Mar 15, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Arrowhead Pharmaceuticals (ARWR) is a near-term hot idea driven by FDA approval of REDEMPLO®, strong cash runway through 2028, positive clinical pipeline progress, ongoing trials with milestone potential, and robust bullish technical momentum (+12% price rise over three weeks) amidst solid industry sentiment.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Rising EBITDA margin • Heavy R&D burn • High net debt ARWR shows improving operating profitability and compressed valuation multiples but remains capital‑intensive with high leverage and strained liquidity.
Price Behavior
Key Price Behavior Insights: • Lower highs • Broken momentum • Wider swings Support Level: $55.01–$55.05 Resistance Level: $64–$65 Over the last month the stock dropped from $62.38 to $55.05 (~11–12%), indicating a clear short-term downtrend with negative momentum and elevated volatility that leaves support near $55.01–$55.05 vulnerable and resistance around $64–$65.
Sentiment & News
Key News Insights: • Institutional repositioning • Q3 clinical wave • Investor engagement Institutional trades and management's investor-roadshow highlight growing investor focus on Arrowhead ahead of multiple expected Q3 clinical readouts that could re-rate the stock.
AI Summary
ARWR has transitioned into an early commercial-stage RNAi company with >$1.3B of new capital and an approved high-value product (REDEMPLO) that can realistically fund pipeline development, but near-term investment outcomes now hinge on rapid commercialization (payer wins and prescription ramp) and pivotal readouts—failure to scale would likely force dilution/debt and sharply compress valuation.
Description
Arrowhead Pharmaceuticals is a Pasadena-based biopharmaceutical company, founded in 1989, that develops RNA interference therapeutics for a range of liver, cardiovascular, pulmonary, rare genetic and oncology indications. Its clinical-stage pipeline includes candidates targeting liver-expressed proteins, cardiovascular lipid regulators, pulmonary targets and other disease-specific genes, and the company partners with Janssen and Takeda on several liver-directed programs. Arrowhead also participates in collaborations for subcutaneously administered RNAi candidates for chronic hepatitis B and other externally developed programs.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 4 | Feb 11 | ARWR | Arrowhead Pharmaceuticals, Inc. | Arrowhead Pharmaceuticals (ARWR) is a near-term hot idea driven by FDA approval of REDEMPLO®, strong cash runway through 2028, positive clinical pipeline progress, ongoing trials with milestone potential, and robust bullish technical momentum (+12% price rise over three weeks) amidst solid industry sentiment. | Closed | -9.6% |
| Dec 2 | Dec 9 | ARWR | Arrowhead Pharmaceuticals, Inc. | Near-term growth opportunity following FDA approval of REDEMPLO (first siRNA therapy for familial chylomicronemia syndrome), Breakthrough Therapy designation for another indication, $200M Novartis upfront payment, and 32.7% price surge supported by strong technical breakout. | Closed | +18.8% |